Summary

The global pharmaceutical excipients market is projected to reach USD 15.99 billion by 2031 from USD 11.95 billion in 2026, at a CAGR of 6.0% during the forecast period. The expansion of the pharmaceutical excipients market has been driven primarily by surging demand for pharmaceutical products and generic medicines, and R&D investments in novel excipient development. Additionally, partnerships & collaborations with pharmaceutical companies and increased emphasis on patient-centric formulations will provide lucrative market growth opportunities. However, regulatory stringency and steep development costs are predicted to restrict the market.

In 2025, the fillers & diluents functionality held the highest share in the pharmaceutical excipients market.

The pharmaceutical excipients market, segmented by functionality, includes binders, suspending and viscosity agents, fillers and diluents, flavoring agents and sweeteners, colorants, coating agents, lubricants and glidants, preservatives, disintegrants, emulsifying agents, and other specialized roles. Among these, fillers and diluents play a critical role, especially in the production of solid oral dosage forms like tablets and capsules. Their importance continues to grow with the rising demand for oral medications, which remain the most preferred route due to ease of administration and patient compliance. Fillers and diluents provide bulk to formulations containing small amounts of active pharmaceutical ingredients and help ensure accurate dosage and improved content uniformity. From a manufacturing perspective, they contribute significantly to formulation stability, ease of processing, and scalability in mass production. They simplify processes such as blending, tableting, and encapsulation while enhancing the mechanical strength of tablets. For patients, these excipients improve mouthfeel, taste, and handling, which are crucial factors for pediatric and geriatric populations. As drug formulations become more complex, the demand for high-performance, multifunctional fillers and diluents that support controlled release and bioavailability enhancement is also rising, presenting significant growth opportunities in this excipient category.

The oral formulations segment accounted for the highest share of the pharmaceutical excipients market in 2025.

The pharmaceutical excipients market is categorized based on formulation types into oral formulations, topical formulations, parenteral formulations, and other formulations. Among these, the oral formulations segment held the largest market share in 2025, reflecting its dominance as the most widely used and traditional drug delivery method. The convenience, cost-effectiveness, and high patient compliance associated with oral administration make it a preferred choice for patients and healthcare providers. This segment continues to expand due to the rising demand for tablets, capsules, and other solid oral dosage forms. Furthermore, the rapid growth of the biopharmaceutical and generics industries is playing a pivotal role in driving demand for high-quality excipients that enhance drug stability, solubility, and bioavailability in oral products. The increasing prevalence of chronic conditions requiring long-term medication and the trend toward self-administration of drugs also contribute to the growth of this segment. As a result, pharmaceutical companies are investing in innovative oral drug formulations, boosting the need for advanced excipients tailored to these needs.

Asia Pacific is expected to grow at the highest CAGR in the global pharmaceutical excipients market from 2026 to 2031.

The pharmaceutical excipients market in the Asia Pacific region is expected to grow robustly and register the highest CAGR among all regions during the forecast period. Several interrelated factors are driving this expansion. One of the key advantages is the region’s cost-effective manufacturing capabilities, which make it an attractive hub for pharmaceutical production and outsourcing. Countries like India, China, and South Korea offer abundant raw material availability, skilled labor, and favorable government policies that support pharmaceutical R&D and export-oriented manufacturing. Additionally, the Asia Pacific region has relatively lenient regulatory frameworks compared to Western markets, which accelerates product development and time-to-market. The rapid rise in per capita income, growing awareness of health and wellness, and increased healthcare spending are further fueling demand for generic drugs and, by extension, pharmaceutical excipients. Moreover, a surge in lifestyle-related chronic diseases and expanding geriatric populations have led to greater demand for innovative drug formulations, including oral solids and topical applications. These trends create significant opportunities for local and global excipient manufacturers to expand operations, invest in infrastructure, and form strategic partnerships to meet the growing regional demand.

The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side-70% and Demand Side-30%
- By Designation: Managers-45%, CXOs & Directors-30%, and Executives-25%
- By Region: North America-40%, Europe-25%, the Asia Pacific-20%, Latin America-10%, and the Middle East & Africa-5%

List of Key Companies Profiled in the Report
Key players in the pharmaceutical excipients market include Roquette Frères (France), ADM (US), , Evonik Industries AG (Germany), BASF SE (Germany), Ashland Inc. (US), Kerry Group plc (Ireland), MERCK KGaA (Germany), Associated British Foods plc (UK), Wacker Chemie AG (Germany), Air Liquide (France), DOW (US), Berkshire Hathaway Inc. (US), Colorcon (US), DFE PHARMA (Germany), Actylis (US), Croda International Plc (UK), Gattefossé (France), JRS Pharma (Germany), and Shin-Etsu Chemical Co., Ltd. (Japan).

Research Coverage
This research report categorizes the pharmaceutical excipients market by Product [(Organic (Oleochemicals, Carbohydrates, Petrochemicals, Proteins, and Other Organic Chemicals), Inorganic (Calcium Phosphate, Metal Oxides, Halites, Calcium Carbonate, Calcium Sulfate, Other Inorganic Chemicals), Other chemicals], by Functionality (Fillers & Diluents, Suspending & Viscosity Agents, Coating Agents, Binders, Flavoring Agents & Sweeteners, Disintegrants, Colorants, Lubricants & Glidants, Preservatives, Emulsifying Agents, and Other Functionalities), by formulation (Oral (Tablets, Capsules, Liquid Formulations and other oral formulations), Topical Formulations, Parenteral Formulations, and Other Formulations), by Functionality Application (Stabilizers, Taste Masking, Modified Release, Solubility & Bioavailability Enhancement and Other Functionality Applications), and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the pharmaceutical excipients market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. The report also covers new approvals/launches, collaborations, acquisitions, and recent developments associated with the pharmaceutical excipients market.

Reasons to Buy this Report
The report will help market leaders and new entrants by providing them with the closest approximations of the revenue numbers for the overall pharmaceutical excipients market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and devise suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:
- Analysis of key drivers (Surging demand for generic medications and pharmaceutical formulations, Increased R&D investments to develop novel excipients, A growing focus on patient-centric drug formulations, Strategic collaborations and partnerships with pharmaceutical firms), restraints (Strict and complex regulatory frameworks, High costs associated with excipient development and manufacturing), opportunities (Increasing interest in functional and multifunctional excipients, Technological advancements, particularly in nanotechnology, Expansion into emerging economies across Asia Pacific and Latin America), and Challenges (Ongoing concerns about excipient safety and quality standards, Limited availability and fluctuating costs of key raw materials).
- Product Development/Innovation: Detailed insights on upcoming products, research and development activities, and new product approvals/launches in the Pharmaceutical Excipients market.
- Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the pharmaceutical excipients market.

Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the pharmaceutical excipients market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 62
1.1 STUDY OBJECTIVES 62
1.2 MARKET DEFINITION 62
1.3 STUDY SCOPE 62
1.3.1 SEGMENTS CONSIDERED 63
1.3.2 INCLUSIONS AND EXCLUSIONS 64
1.3.3 YEARS CONSIDERED 65
1.3.4 CURRENCY CONSIDERED 65
1.4 STAKEHOLDERS 65
1.5 SUMMARY OF CHANGES 66

2 EXECUTIVE SUMMARY 67
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 67
2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS 69
2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH 70
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 71
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 72

3 PREMIUM INSIGHTS 73
3.1 GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET SNAPSHOT 73
3.2 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION AND COUNTRY, 2025 74
3.3 PHARMACEUTICAL EXCIPIENTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 75

4 MARKET OVERVIEW 76
4.1 INTRODUCTION 76
4.2 MARKET DYNAMICS 76
4.2.1 DRIVERS 77
4.2.1.1 Surging demand for generic medications and pharmaceutical formulations 77
4.2.1.2 Increased R&D investments to develop novel excipients 79
4.2.1.3 Growing focus on patient-centric drug formulations 80
4.2.1.4 Collaborations and partnerships among pharmaceutical firms 81
4.2.2 RESTRAINTS 81
4.2.2.1 Strict and complex regulatory frameworks 81
4.2.2.2 High cost of excipient development and manufacturing 82
4.2.3 OPPORTUNITIES 83
4.2.3.1 Increasing interest in functional and multifunctional excipients 83
4.2.3.2 Technological advancements in nanotechnology 84
4.2.3.3 Market opportunities in emerging economies 85
4.2.4 CHALLENGES 86
4.2.4.1 Ongoing concerns about excipient safety and quality standards 86
4.2.4.2 Limited availability and fluctuating costs of key raw materials 87
4.3 UNMET NEEDS & WHITE SPACES 87
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 89
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 89

5 INDUSTRY TRENDS 91
5.1 PORTER’S FIVE FORCES ANALYSIS 91
5.1.1 BARGAINING POWER OF SUPPLIERS 92
5.1.2 BARGAINING POWER OF BUYERS 92
5.1.3 THREAT OF NEW ENTRANTS 93
5.1.4 THREAT OF SUBSTITUTES 93
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 93
5.2 MACROECONOMIC OUTLOOK 93
5.2.1 INTRODUCTION 93
5.2.2 GDP TRENDS AND FORECAST 94
5.2.3 TRENDS IN GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET 94
5.2.4 TRENDS IN HEALTHCARE EXPENDITURE 95
5.3 VALUE CHAIN ANALYSIS 97
5.4 SUPPLY CHAIN ANALYSIS 99
5.5 ECOSYSTEM ANALYSIS 100
5.6 PRICING ANALYSIS 102
5.6.1 INDICATIVE PRICING ANALYSIS, BY KEY PLAYER, 2025 102
5.6.2 INDICATIVE PRICING ANALYSIS, BY REGION, 2025 103
5.7 TRADE ANALYSIS 104
5.7.1 TRADE DATA (HS CODE 290545) 104
5.7.1.1 Import data for HS code 290545 104
5.7.1.2 Export data for HS code 290545 105
5.7.2 TRADE DATA (HS CODE 350510) 106
5.7.2.1 Import data for HS code 350510 106
5.7.2.2 Export data for HS code 350510 107
5.7.3 TRADE DATA (HS CODE 290532) 108
5.7.3.1 Import data for HS code 290532 108
5.7.3.2 Export data for HS code 290532 109
5.7.4 TRADE DATA (HS CODE 283650) 110
5.7.4.1 Import data for HS code 283650 110
5.7.4.2 Export data for HS code 283650 111
5.7.5 TRADE DATA (HS CODE 250100) 112
5.7.5.1 Import data for HS code 250100 112
5.7.5.2 Export data for HS code 250100 113
5.7.6 TRADE DATA (HS CODE 290543) 114
5.7.6.1 Import data for HS code 290543 114
5.7.6.2 Export data for HS code 290543 115
5.7.7 TRADE DATA (HS CODE 3912) 116
5.7.7.1 Import data for HS code 3912 116
5.7.7.2 Export data for HS code 3912 117
5.8 KEY CONFERENCES & EVENTS 118
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 120
5.10 INVESTMENT/FUNDING ACTIVITY 121
5.11 CASE STUDY ANALYSIS 122
5.11.1 CASE STUDY 1: MOISTURE PROTECTION FOR MOISTURE-SENSITIVE TABLETS 122
5.11.2 CASE STUDY 2: STABILIZATION OF MONOCLONAL ANTIBODY FORMULATIONS 122
5.12 IMPACT OF 2025 US TARIFFS—PHARMACEUTICAL EXCIPIENTS MARKET 123
5.12.1 INTRODUCTION 123
5.12.2 KEY TARIFF RATES 123
5.12.3 PRICE IMPACT ANALYSIS 124
5.12.4 COMPARATIVE PRICING ON KEY EXCIPIENT PRE AND POST US 2025 TARIFFS 124
5.12.5 IMPACT ON COUNTRIES/REGIONS 125
5.12.5.1 North America 125
5.12.5.1.1 US 125
5.12.5.2 Europe 125
5.12.5.3 Asia Pacific 125
5.12.6 IMPACT ON END-USE INDUSTRIES 125

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 127
6.1 TECHNOLOGY ANALYSIS 127
6.1.1 KEY TECHNOLOGIES 127
6.1.1.1 Co-processed excipient technology 127
6.1.1.2 Nanotechnology-based excipients 127
6.1.2 COMPLEMENTARY TECHNOLOGIES 127
6.1.2.1 3D printing/additive manufacturing 127
6.1.2.2 Process Analytical Technology (PAT) 127
6.1.3 ADJACENT TECHNOLOGIES 127
6.1.3.1 Artificial intelligence in formulation design 127
6.1.3.2 Green chemistry/sustainability tech 128
6.2 TECHNOLOGY/PRODUCT ROADMAP 128
6.3 PATENT ANALYSIS 128
6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR PHARMACEUTICAL EXCIPIENTS PATENTS, 2015–2025 129
6.4 FUTURE APPLICATIONS 130
6.5 IMPACT OF AI/GEN AI ON PHARMACEUTICAL EXCIPIENTS MARKET 131
6.5.1 INTRODUCTION 131
6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN PHARMACEUTICAL EXCIPIENTS MARKET 131
6.5.3 AI USE CASES 132
6.5.4 KEY COMPANIES IMPLEMENTING AI 133
6.5.5 FUTURE OF GENERATIVE AI IN PHARMACEUTICAL EXCIPIENT ECOSYSTEM 134
6.6 SUCCESS STORIES AND REAL-WORLD APPLICATIONS 134

7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 136
7.1 REGULATORY LANDSCAPE 136
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 136
7.1.2 REGULATORY FRAMEWORK 139
7.1.2.1 US 139
7.1.2.2 Europe 139
7.1.2.3 China 140
7.1.2.4 India 140
7.1.2.5 Brazil 140
7.1.3 INDUSTRY STANDARDS 141
7.2 SUSTAINABILITY INITIATIVES 141
7.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 142

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 143
8.1 DECISION-MAKING PROCESS 143
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 144
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 144
8.2.2 KEY BUYING CRITERIA, BY END USER 145
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 146
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 146
8.5 MARKET PROFITABILITY 147

9 PHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT 148
9.1 INTRODUCTION 149
9.2 ORGANIC CHEMICALS 149
9.2.1 OLEOCHEMICALS 152
9.2.1.1 Fatty alcohols 155
9.2.1.1.1 Wide usage of fatty alcohols as nonionic surfactants due to their amphipathic nature to drive market growth 155
9.2.1.2 Mineral stearates 157
9.2.1.3 Wide use of magnesium stearates as excipients in nutraceutical and pharmaceutical formulations to drive market growth 157
9.2.1.4 Glycerin 160
9.2.1.4.1 Extensive applications of glycerin to drive market growth 160
9.2.1.5 Other oleochemicals 162
9.2.2 CARBOHYDRATES 164
9.2.2.1 Sugars 167
9.2.2.2 Actual sugars 170
9.2.2.3 Lactose 173
9.2.2.3.1 Superior compressibility and widespread use in solid oral dosage forms to propel segment growth 173
9.2.2.4 Sucrose 175
9.2.2.4.1 Increasing usage of sucrose in pediatric, oral liquid, and lyophilized biologic formulations to drive growth 175
9.2.2.5 Dextrose (D-Glucose) 177
9.2.2.5.1 Growing use of dextrose in injectable and rehydration therapies to support growth 177
9.2.2.6 Sugar alcohols 180
9.2.2.7 Sorbitol 183
9.2.2.7.1 Rising demand for sorbitol as stabilizer and sweetening agent in liquid and chewable formulations to fuel market 183
9.2.2.8 Mannitol 185
9.2.2.8.1 Expanding use of mannitol in solid dosage and lyophilized biologics due to its non-hygroscopic and stabilizing properties to aid growth 185
9.2.2.9 Other sugar alcohols 187
9.2.2.10 Artificial sweeteners 190
9.2.2.10.1 Wide usage of aspartame as artificial sweetener to drive market growth 190
9.2.2.11 Cellulose 193
9.2.2.12 Microcrystalline cellulose 196
9.2.2.12.1 Most widely used excipient in direct compression method for tablets to boost market 196
9.2.2.13 Cellulose ethers 198
9.2.2.13.1 Highly effective even at lower concentrations to boost demand for cellulose ethers 198
9.2.2.14 CMC & croscarmellose sodium 201
9.2.2.14.1 Multiple advantages of CMC and croscarmellose sodium to drive market growth 201
9.2.2.15 Cellulose esters 204
9.2.2.15.1 Delivery of drugs in cellular membranes and intracellular matrix to support market growth 204
9.2.2.16 Starch 206
9.2.2.17 Modified starch 209
9.2.2.17.1 Growing use in sustained-release tablets due to its cold-water swelling and gel barrier formation capabilities to drive market growth 209
9.2.2.18 Dried starch 211
9.2.2.18.1 Strong binding and coating agent to boost adoption 211
9.2.2.19 Converted starch 214
9.2.2.19.1 Growing use of converted starch as molecular encapsulation agent to support market 214
9.2.3 PETROCHEMICALS 216
9.2.3.1 Glycols 219
9.2.3.1.1 Availability of highly purified polyethylene glycol to enhance market demand 219
9.2.3.2 Polyethylene glycol (PEG) 222
9.2.3.2.1 Increasing adoption of PEG as versatile excipient in topical, oral, and parenteral formulations to boost market 222
9.2.3.3 Propylene glycol (PG) 224
9.2.3.3.1 Rising use in oral and injectable formulations for solvent, humectant, and preservative-enhancing functions to boost demand 224
9.2.3.4 Povidones 227
9.2.3.4.1 Rising demand for fast-dissolving tablets to propel growth 227
9.2.3.5 Mineral hydrocarbons 229
9.2.3.5.1 Growing preference for topical formulations in pain management to support demand for mineral hydrocarbons 229
9.2.3.6 Petrolatum 232
9.2.3.6.1 Occlusive and emollient properties of petrolatum to drive adoption 232
9.2.3.7 Mineral waxes 234
9.2.3.7.1 Utilization of mineral waxes in solid and semi-solid dosage forms for structure enhancement and controlled drug release to boost market 234
9.2.3.8 Mineral oils 237
9.2.3.8.1 Extensive use of mineral oils as solvents and emollients in topical, oral, and parenteral pharmaceutical applications to drive growth 237
9.2.3.9 Acrylic polymers 239
9.2.3.9.1 Wide use of acrylic polymers in controlled-release drug formulations to drive market growth 239
9.2.3.10 Other petrochemical excipients 242
9.2.4 PROTEINS 245
9.2.4.1 Growing applications of proteins as carriers for microparticles and nanoparticles to drive market growth 245
9.2.5 OTHER ORGANIC CHEMICALS 247
9.3 INORGANIC CHEMICALS 250
9.3.1 CALCIUM PHOSPHATE 252
9.3.1.1 Chemical purity and low incompatibility with drugs to aid their high usage in pharmaceutical industry 252
9.3.2 METAL OXIDES 255
9.3.2.1 Availability of silicon oxides in hydrophobic, hydrophilic, and granulated forms to aid market growth 255
9.3.3 HALITES 257
9.3.3.1 Increased utilization of halites in vaccines and controlled-release formulations to drive market demand 257
9.3.4 CALCIUM CARBONATE 260
9.3.4.1 Properties such as short disintegration time and excellent mechanical strength to drive market 260
9.3.5 CALCIUM SULFATE 262
9.3.5.1 Advantages such as cost-effective, quality-enhancing diluent for solid dosage forms to boost demand 262
9.3.6 OTHER INORGANIC CHEMICALS 264
9.4 OTHER CHEMICALS 267

10 PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION 270
10.1 INTRODUCTION 271
10.2 ORAL FORMULATIONS 271
10.2.1 TABLETS 274
10.2.1.1 Wide usage of tablets to support market growth 274
10.2.2 CAPSULES 277
10.2.2.1 Hard-gelatin capsules 280
10.2.2.1.1 Ease of manufacturing and versatility to drive growth of hard-gelatin capsules market 280
10.2.2.2 Soft-gelatin capsules 282
10.2.2.2.1 Stability concerns with highly water-soluble compounds and compounds susceptible to hydrolysis to restrict market growth 282
10.2.3 LIQUID FORMULATIONS 285
10.2.3.1 Liquid formulations require no dissolution time and boast faster absorption from stomach than tablets—key factors driving growth 285
10.2.4 OTHER ORAL FORMULATIONS 288
10.3 TOPICAL FORMULATIONS 290
10.3.1 ADVANTAGES OF TOPICAL DRUG DELIVERY TO DRIVE DEMAND FOR EXCIPIENTS IN THIS SEGMENT 290
10.4 PARENTERAL FORMULATIONS 293
10.4.1 EMERGENCE OF NEW BIOLOGICAL MOLECULES TO INCREASE DEMAND FOR EXCIPIENTS 293
10.5 OTHER FORMULATIONS 297

11 PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY 300
11.1 INTRODUCTION 301
11.2 FILLERS & DILUENTS 301
11.2.1 IMPROVED COHESION, DIRECT COMPRESSION, AND FLOW TO FINAL DOSE IN TABLETS TO BOOST MARKET DEMAND 301
11.3 SUSPENDING & VISCOSITY AGENTS 304
11.3.1 ADVANTAGES SUCH AS DRUG STABILITY AND TASTE MASKING TO BOOST MARKET GROWTH 304
11.4 COATING AGENTS 307
11.4.1 INCREASING USE OF SUSTAINED-RELEASE FORMULATIONS IN PHARMA INDUSTRY TO DRIVE MARKET GROWTH 307
11.5 BINDERS 310
11.5.1 FLUIDITY AND COMPRESSIBILITY ESSENTIAL FOR TABLET MANUFACTURING ASSOCIATED WITH BINDERS TO SUPPORT MARKET 310
11.6 FLAVORING AGENTS & SWEETENERS 313
11.6.1 ABILITY TO IMPROVE PALATABILITY OF DRUGS TO DRIVE DEMAND 313
11.7 DISINTEGRANTS 316
11.7.1 ABILITY TO CAUSE RAPID BREAK-UP OF SOLID DOSAGE FORMS TO BOOST ADOPTION 316
11.8 COLORANTS 319
11.8.1 GROWING USE IN HARD AND SOFT GELATIN CAPSULES, TABLETS, ORAL LIQUIDS, AND TOPICAL CREAMS TO FUEL GROWTH 319
11.9 LUBRICANTS & GLIDANTS 322
11.9.1 ABILITY TO IMPROVE FLOW PROPERTIES OF FORMULATIONS BY REDUCING INTERPARTICLE FRICTION AND COHESION TO DRIVE GROWTH 322
11.10 PRESERVATIVES 324
11.10.1 GROWING USE OF BENZYL ALCOHOL IN PHARMACEUTICAL AND NUTRACEUTICAL INDUSTRIES TO SUPPORT GROWTH 324
11.11 EMULSIFYING AGENTS 327
11.11.1 USE OF SOLUBILITY ENHANCEMENT EXCIPIENTS IN LIQUID DRUG FORMULATIONS TO INCREASE API BIOAVAILABILITY TO DRIVE DEMAND 327
11.12 OTHER FUNCTIONALITIES 330

12 PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY APPLICATION 334
12.1 INTRODUCTION 335
12.2 STABILIZERS 335
12.2.1 ADVANTAGES SUCH AS IMPROVED DRUG SHELF LIFE AND FEWER MANUFACTURING DEFECTS TO BOOST DEMAND 335
12.3 TASTE MASKING 338
12.3.1 BENEFITS SUCH AS GREATER PATIENT COMPLIANCE AND ADHERENCE TO MEDICATION REGIMENS TO FUEL MARKET 338
12.4 MODIFIED-RELEASE 341
12.4.1 INCREASING USE OF MODIFIED-RELEASE FORMULATIONS IN PHARMA INDUSTRY TO DRIVE MARKET GROWTH 341
12.5 SOLUBILITY & BIOAVAILABILITY ENHANCEMENT 344
12.5.1 ESSENTIAL NATURE OF SOLUBILITY AND BIOAVAILABILITY FORMULATIONS FOR EFFECTIVE DRUG DELIVERY TO BOOST ADOPTION 344
12.6 OTHER FUNCTIONALITY APPLICATIONS 347

13 PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION 351
13.1 INTRODUCTION 352
13.2 EUROPE 352
13.2.1 GERMANY 361
13.2.1.1 Germany accounted for largest share of European pharmaceutical excipients market in 2025 361
13.2.2 UK 368
13.2.2.1 Growing adoption of generics and development of novel multi-functional, co-processed excipients to drive market growth 368
13.2.3 FRANCE 375
13.2.3.1 Large geriatric population in country to support market growth 375
13.2.4 ITALY 382
13.2.4.1 Budgetary constraints and restricted healthcare spending to impede growth of Italian market 382
13.2.5 SPAIN 389
13.2.5.1 High consumption of biologics to support market growth 389
13.2.6 REST OF EUROPE 396
13.3 NORTH AMERICA 403
13.3.1 US 410
13.3.1.1 US to dominate North American market 410
13.3.2 CANADA 417
13.3.2.1 Strong growth of emerging markets and slowdown in new product approvals to hamper market growth in Canada 417
13.4 ASIA PACIFIC 424
13.4.1 CHINA 432
13.4.1.1 Emphasis on generics and off-patent drugs to drive market in China 432
13.4.2 JAPAN 439
13.4.2.1 Rapid growth of Japan’s geriatric population to greatly drive demand for pharmaceuticals 439
13.4.3 INDIA 446
13.4.3.1 Leading producer of generics to drive growth in India market 446
13.4.4 SOUTH KOREA 454
13.4.4.1 Presence of leading contract research and development organizations to propel market growth 454
13.4.5 REST OF ASIA PACIFIC 461
13.5 LATIN AMERICA 468
13.5.1 BRAZIL 475
13.5.1.1 Emerging opportunities for excipient manufacturers in Brazil to boost growth 475
13.5.2 MEXICO 482
13.5.2.1 Growing demand for affordable therapies and contract manufacturing to support growth 482
13.5.3 REST OF LATIN AMERICA 489
13.6 MIDDLE EAST 496
13.6.1 GCC COUNTRIES 503
13.6.1.1 healthcare infrastructure expansion and localization of drug manufacturing to drive excipients market in GCC Countries 503
13.6.2 REST OF MIDDLE EAST 510
13.7 AFRICA 517
13.7.1 UNSATURATED MARKETS IN THE REGION HAVE DRAWN THE ATTENTION OF GLOBAL PLAYERS 517

14 COMPETITIVE LANDSCAPE 524
14.1 INTRODUCTION 524
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 524
14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PHARMACEUTICAL EXCIPIENTS MARKET, 2023−2026 524
14.3 REVENUE ANALYSIS, 2023–2025 525
14.4 MARKET SHARE ANALYSIS, 2025 526
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 528
14.5.1 STARS 528
14.5.2 EMERGING LEADERS 528
14.5.3 PERVASIVE PLAYERS 529
14.5.4 PARTICIPANTS 529
14.5.5 COMPETITIVE BENCHMARKING: KEY PLAYERS, 2025 530
14.5.5.1 Company footprint 530
14.5.5.2 Region footprint 531
14.5.5.3 Product footprint 532
14.5.5.4 Functionality footprint 533
14.5.5.5 Functionality application footprint 534
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 535
14.6.1 PROGRESSIVE COMPANIES 535
14.6.2 RESPONSIVE COMPANIES 535
14.6.3 DYNAMIC COMPANIES 535
14.6.4 STARTING BLOCKS 535
14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 537
14.6.5.1 Detailed list of key startups/SMEs 537
14.6.5.2 Competitive benchmarking of key startups/SMEs 538
14.7 COMPANY VALUATION AND FINANCIAL METRICS 539
14.8 BRAND/PRODUCT COMPARISON 540
14.9 COMPETITIVE SCENARIO 541
14.9.1 PRODUCT APPROVALS & LAUNCHES 541
14.9.2 DEALS 542
14.9.3 EXPANSIONS 543

15 COMPANY PROFILES 544
15.1 KEY PLAYERS 544
15.1.1 ROQUETTE FRÈRES 544
15.1.1.1 Business overview 544
15.1.1.2 Products offered 545
15.1.1.3 Recent developments 551
15.1.1.3.1 Product launches 551
15.1.1.3.2 Deals 551
15.1.1.4 MnM view 551
15.1.1.4.1 Key strengths 551
15.1.1.4.2 Strategic choices 552
15.1.1.4.3 Weaknesses and competitive threats 552
15.1.2 ARCHER-DANIELS-MIDLAND COMPANY 553
15.1.2.1 Business overview 553
15.1.2.2 Products offered 555
15.1.2.3 Recent developments 556
15.1.2.3.1 Deals 556
15.1.2.4 MnM view 556
15.1.2.4.1 Key strengths 556
15.1.2.4.2 Strategic choices 556
15.1.2.4.3 Weaknesses and competitive threats 556
15.1.3 BASF SE 557
15.1.3.1 Business overview 557
15.1.3.2 Products offered 559
15.1.3.3 Recent developments 562
15.1.3.3.1 Deals 562
15.1.3.3.2 Expansions 562
15.1.3.4 MnM view 562
15.1.3.4.1 Key strengths 562
15.1.3.4.2 Strategic choices 563
15.1.3.4.3 Weaknesses and competitive threats 563
15.1.4 EVONIK INDUSTRIES AG 564
15.1.4.1 Business overview 564
15.1.4.2 Products offered 566
15.1.4.3 Recent developments 567
15.1.4.3.1 Expansions 567
15.1.4.4 MnM view 567
15.1.4.4.1 Key strengths 567
15.1.4.4.2 Strategic choices 567
15.1.4.4.3 Weaknesses and competitive threats 567
15.1.5 ASHLAND INC. 568
15.1.5.1 Business overview 568
15.1.5.2 Products offered 569
15.1.5.3 Recent developments 571
15.1.5.3.1 Product launches and approvals 571
15.1.5.4 MnM view 572
15.1.5.4.1 Key strengths 572
15.1.5.4.2 Strategic choices 573
15.1.5.4.3 Weaknesses and competitive threats 573
15.1.6 KERRY GROUP PLC 574
15.1.6.1 Business overview 574
15.1.6.2 Products offered 575
15.1.6.3 Recent developments 577
15.1.6.3.1 Deals 577
15.1.7 MERCK KGAA 578
15.1.7.1 Business overview 578
15.1.7.2 Products offered 579
15.1.7.3 Recent developments 581
15.1.7.3.1 Deals 581
15.1.8 ASSOCIATED BRITISH FOODS PLC 582
15.1.8.1 Business overview 582
15.1.8.2 Products offered 583
15.1.8.3 Recent developments 586
15.1.8.3.1 Deals 586
15.1.9 WACKER CHEMIE AG 587
15.1.9.1 Business overview 587
15.1.9.2 Products offered 588
15.1.10 AIR LIQUIDE S.A. 589
15.1.10.1 Business overview 589
15.1.10.2 Products offered 590
15.1.10.3 Recent developments 593
15.1.10.3.1 Product launches 593
15.1.11 DOW INC. 594
15.1.11.1 Business overview 594
15.1.11.2 Products offered 595
15.1.12 BERKSHIRE HATHAWAY INC. (LUBRIZOL CORPORATION) 596
15.1.12.1 Business overview 596
15.1.12.2 Products offered 597
15.1.13 COLORCON, INC. 599
15.1.13.1 Business overview 599
15.1.13.2 Products offered 599
15.1.13.3 Recent developments 600
15.1.13.3.1 Product launches 600
15.1.13.3.2 Deals 601
15.1.13.3.3 Expansions 601
15.1.14 DFE PHARMA GMBH & CO. KG 602
15.1.14.1 Business overview 602
15.1.14.2 Products offered 602
15.1.15 ACTYLIS 605
15.1.15.1 Business overview 605
15.1.15.2 Products offered 605
15.1.15.3 Recent developments 610
15.1.15.3.1 Deals 610
15.1.16 CRODA INTERNATIONAL PLC 611
15.1.16.1 Business overview 611
15.1.16.2 Products offered 612
15.1.16.3 Recent developments 612
15.1.16.3.1 Deals 612
15.1.16.3.2 Expansions 613
15.1.17 GATTEFOSSÉ SAS 614
15.1.17.1 Business overview 614
15.1.17.2 Products offered 614
15.1.18 J. RETTENMAIER & SÖHNE GMBH + CO KG 616
15.1.18.1 Business overview 616
15.1.18.2 Products offered 616
15.1.19 SHIN-ETSU CHEMICAL CO., LTD. 618
15.1.19.1 Business overview 618
15.1.19.2 Products offered 619
15.1.19.3 Recent developments 620
15.1.19.3.1 Deals 620
15.1.19.3.2 Expansions 621
15.2 OTHER PLAYERS 622
15.2.1 INNOPHOS HOLDINGS, INC. 622
15.2.2 MEGGLE GMBH & CO. KG 623
15.2.3 FUJI CHEMICAL INDUSTRIES CO., LTD. 624
15.2.4 COREL PHARMA CHEM PVT. LTD. 625
15.2.5 BIOGRUND GMBH 626
15.2.6 NITIKA PHARMACEUTICAL SPECIALTIES PVT. LTD. 627
15.2.7 R.T. VANDERBILT HOLDING COMPANY, INC. 628
15.2.8 BENEO GMBH 629
15.2.9 SIGACHI INDUSTRIES LIMITED 630
15.2.10 JH NANHANG LIFE SCIENCES CO., LTD. 631

16 RESEARCH METHODOLOGY 632
16.1 RESEARCH DATA 632
16.1.1 SECONDARY DATA 633
16.1.1.1 Objectives of secondary research 633
16.1.1.2 Key data from secondary sources 634
16.1.2 PRIMARY DATA 634
16.1.2.1 Breakdown of primaries (supply- and demand-side participants) 635
16.1.2.2 Key objective of primary research 635
16.2 MARKET ESTIMATION 636
16.2.1 GLOBAL MARKET ESTIMATION 636
16.2.1.1 Company revenue analysis (bottom-up approach) 636
16.2.1.2 Revenue share analysis of Roquette Frères 637
16.2.1.3 MnM repository analysis 638
16.2.1.4 Primary interviews 638
16.2.2 INSIGHTS FROM PRIMARY EXPERTS 639
16.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH) 639
16.3 MARKET GROWTH RATE PROJECTIONS 641
16.4 DATA TRIANGULATION 642
16.5 STUDY ASSUMPTIONS 643
16.6 RESEARCH LIMITATIONS 644
16.7 RISK ANALYSIS 644

17 APPENDIX 645
17.1 DISCUSSION GUIDE 645
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 650
17.3 CUSTOMIZATION OPTIONS 652
17.4 RELATED REPORTS 652
17.5 AUTHOR DETAILS 653

ページTOPに戻る

List of Tables/Graphs

FIGURE 1 PHARMACEUTICAL EXCIPIENTS MARKET: SEGMENTS CONSIDERED 63.
FIGURE 2 REGIONAL SCOPE 64.
FIGURE 3 PHARMACEUTICAL EXCIPIENTS MARKET: YEARS CONSIDERED 65.
FIGURE 4 MARKET SCENARIO 68.
FIGURE 5 GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET, 2024–2031 68.
FIGURE 6 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN PHARMACEUTICAL EXCIPIENTS MARKET, 2023–2025 69.
FIGURE 7 DISRUPTIONS INFLUENCING GROWTH OF PHARMACEUTICAL EXCIPIENTS MARKET 70.
FIGURE 8 HIGH-GROWTH SEGMENTS IN PHARMACEUTICAL EXCIPIENTS MARKET,.
2026–2031 71.
FIGURE 9 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN PHARMACEUTICAL EXCIPIENTS, IN TERMS OF VALUE, DURING FORECAST PERIOD 72.
FIGURE 10 INCREASING SIZE OF CLINICAL DEVELOPMENT PIPELINE TO PROPEL MARKET GROWTH 73.
FIGURE 11 US AND ORAL FORMULATIONS SEGMENT COMMANDED LARGEST MARKET SHARES IN 2025 74.
FIGURE 12 GERMANY TO REGISTER HIGHER CAGR DURING FORECAST PERIOD 75.
FIGURE 13 PHARMACEUTICAL EXCIPIENTS MARKET: DRIVERS, RESTRAINTS,.
OPPORTUNITIES, AND CHALLENGES 76.
FIGURE 14 GLOBAL PHARMACEUTICAL R&D SPEND, 2018–2028 79.
FIGURE 15 PHARMACEUTICAL EXCIPIENTS MARKET: PORTER’S FIVE FORCES ANALYSIS 92.
FIGURE 16 PHARMACEUTICAL EXCIPIENTS MARKET: VALUE CHAIN ANALYSIS 98.
FIGURE 17 PHARMACEUTICAL EXCIPIENTS MARKET: SUPPLY CHAIN ANALYSIS 99.
FIGURE 18 PHARMACEUTICAL EXCIPIENTS MARKET: ECOSYSTEM ANALYSIS 100.
FIGURE 19 INDICATIVE PRICING ANALYSIS, BY PRODUCT TYPE, 2025 (USD/KG) 103.
FIGURE 20 INDICATIVE PRICING ANALYSIS OF PRODUCT TYPES, BY REGION, 2025 (USD/KG) 104.
FIGURE 21 PHARMACEUTICAL EXCIPIENTS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 120.
FIGURE 22 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE 121.
FIGURE 23 TOP APPLICANTS/OWNERS (COMPANIES) FOR PHARMACEUTICAL EXCIPIENTS PATENTS, 2015–2025 129.
FIGURE 24 PHARMACEUTICAL EXCIPIENTS MARKET: AI USE CASES 132.
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT 144.
FIGURE 26 KEY BUYING CRITERIA, BY END USER 145.
FIGURE 27 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET SNAPSHOT 353.
FIGURE 28 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET SNAPSHOT 425.
FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS, 2023–2025 (USD MILLION) 526.
FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025 527.
FIGURE 31 PHARMACEUTICAL EXCIPIENTS MARKET: COMPANY EVALUATION MATRIX.
(KEY PLAYERS), 2025 529.
FIGURE 32 PHARMACEUTICAL EXCIPIENTS MARKET: COMPANY FOOTPRINT 530.
FIGURE 33 PHARMACEUTICAL EXCIPIENTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 536.
FIGURE 34 EV/EBITDA OF KEY VENDORS 539.
FIGURE 35 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK.
BETA OF KEY VENDORS 539.
FIGURE 36 PHARMACEUTICAL EXCIPIENTS MARKET: BRAND/PRODUCT COMPARISON 540.
FIGURE 37 ROQUETTE FRÈRES: COMPANY SNAPSHOT (2025) 545.
FIGURE 38 ARCHER-DANIELS-MIDLAND COMPANY: COMPANY SNAPSHOT (2025) 554.
FIGURE 39 BASF SE: COMPANY SNAPSHOT (2025) 558.
FIGURE 40 EVONIK INDUSTRIES AG: COMPANY SNAPSHOT (2025) 565.
FIGURE 41 ASHLAND INC.: COMPANY SNAPSHOT (2025) 569.
FIGURE 42 KERRY GROUP PLC: COMPANY SNAPSHOT (2025) 575.
FIGURE 43 MERCK KGAA: COMPANY SNAPSHOT (2025) 579.
FIGURE 44 ASSOCIATED BRITISH FOODS PLC: COMPANY SNAPSHOT (2025) 583.
FIGURE 45 WACKER CHEMIE AG: COMPANY SNAPSHOT (2025) 588.
FIGURE 46 AIR LIQUIDE S.A.: COMPANY SNAPSHOT (2025) 590.
FIGURE 47 DOW INC.: COMPANY SNAPSHOT (2025) 594.
FIGURE 48 BERKSHIRE HATHAWAY INC.: COMPANY SNAPSHOT (2025) 596.
FIGURE 49 CRODA INTERNATIONAL PLC: COMPANY SNAPSHOT (2025) 611.
FIGURE 50 SHIN-ETSU CHEMICAL CO., LTD.: COMPANY SNAPSHOT (2025) 619.
FIGURE 51 PHARMACEUTICAL EXCIPIENTS MARKET: RESEARCH DESIGN 632.
FIGURE 52 PHARMACEUTICAL EXCIPIENTS MARKET: KEY DATA FROM SECONDARY SOURCES 634.
FIGURE 53 PHARMACEUTICAL EXCIPIENTS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS 635.
FIGURE 54 PHARMACEUTICAL EXCIPIENTS MARKET SIZE ESTIMATION.
(SUPPLY-SIDE ANALYSIS), 2025 636.
FIGURE 55 COMPANY REVENUE ANALYSIS-BASED ESTIMATION:.
BOTTOM-UP APPROACH (2025) 637.
FIGURE 56 REVENUE SHARE ANALYSIS OF ROQUETTE FRÈRES (FRANCE) (2025) 637.
FIGURE 57 PHARMACEUTICAL EXCIPIENTS MARKET SIZE VALIDATION.
FROM PRIMARY SOURCES 639.
FIGURE 58 PHARMACEUTICAL EXCIPIENTS MARKET: TOP-DOWN APPROACH 640.
FIGURE 59 PHARMACEUTICAL EXCIPIENTS MARKET: CAGR PROJECTIONS 641.
FIGURE 60 PHARMACEUTICAL EXCIPIENTS MARKET: DATA TRIANGULATION 643.
TABLE 1 PHARMACEUTICAL EXCIPIENTS MARKET: INCLUSIONS AND EXCLUSIONS 64.
TABLE 2 PHARMACEUTICAL EXCIPIENTS MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 77.
TABLE 3 IMPENDING AND ONGOING PATENT EXPIRY OF BLOCKBUSTER THERAPEUTICS,.
2023–2035 78.
TABLE 4 LIST OF MULTIFUNCTIONAL EXCIPIENTS 84.
TABLE 5 ACTIVE PHARMACEUTICAL INGREDIENTS (API) MERCHANT MARKET, BY REGION,.
2023–2031 (USD MILLION) 89.
TABLE 6 PHARMACEUTICAL EXCIPIENTS MARKET: PORTER’S FIVE FORCES ANALYSIS 91.
TABLE 7 HEALTH EXPENDITURE AND FINANCING, 2015–2024 (IN PERCENTAGE OF GDP) 96.
TABLE 8 PHARMACEUTICAL EXCIPIENTS MARKET: ROLE IN ECOSYSTEM 101.
TABLE 9 INDICATIVE PRICING ANALYSIS OF PRODUCT TYPES, BY KEY PLAYER,.
2025 (USD/KG) 102.
TABLE 10 INDICATIVE PRICING ANALYSIS OF EXCIPIENTS, BY REGION, 2025 (USD/KG) 103.
TABLE 11 IMPORT DATA FOR HS CODE 290545 (GLYCEROL), 2021–2025 (USD) 104.
TABLE 12 IMPORT DATA FOR HS CODE 290545 (GLYCEROL), 2021–2025 (TONS) 105.
TABLE 13 EXPORT DATA FOR HS CODE 290545 (GLYCEROL), 2021–2025 (USD) 105.
TABLE 14 EXPORT DATA FOR HS CODE 290545 (GLYCEROL), 2021–2025 (TONS) 106.
TABLE 15 IMPORT DATA FOR HS CODE 350510 (DEXTRINS AND OTHER MODIFIED STARCHES, E.G. PREGELATINIZED OR ESTERIFIED STARCHES), 2021–2025 (USD) 106.
TABLE 16 IMPORT DATA FOR HS CODE 350510 (DEXTRINS AND OTHER MODIFIED STARCHES, E.G. PREGELATINIZED OR ESTERIFIED STARCHES), 2021–2025 (TONS) 107.
TABLE 17 EXPORT DATA FOR HS CODE 350510 (DEXTRINS AND OTHER MODIFIED STARCHES, E.G. PREGELATINIZED OR ESTERIFIED STARCHES), 2021–2025 (USD) 107.
TABLE 18 EXPORT DATA FOR HS CODE 350510 (DEXTRINS AND OTHER MODIFIED STARCHES, E.G. PREGELATINIZED OR ESTERIFIED STARCHES), 2021–2025 (TONS) 108.
TABLE 19 IMPORT DATA FOR HS CODE 290532 (PROPYLENE GLYCOL "PROPANE-1,2-DIOL),.
2021–2025 (USD) 108.
TABLE 20 IMPORT DATA FOR HS CODE 290532 (PROPYLENE GLYCOL "PROPANE-1,2-DIOL),.
2021–2025 (TONS) 109.
TABLE 21 EXPORT DATA FOR HS CODE 290532 (PROPYLENE GLYCOL/PROPANE-1,2-DIOL),.
2021–2025 (USD) 109.
TABLE 22 EXPORT DATA FOR HS CODE 290532 (PROPYLENE GLYCOL/PROPANE-1,2-DIOL),.
2021–2025 (TONS) 110.
TABLE 23 IMPORT DATA FOR HS CODE 283650 (CALCIUM CARBONATE), 2021–2025 (USD) 110.
TABLE 24 IMPORT DATA FOR HS CODE 283650 (CALCIUM CARBONATE), 2021–2025 (TONS) 111.
TABLE 25 EXPORT DATA FOR HS CODE 283650 (CALCIUM CARBONATE), 2021–2025 (USD) 111.
TABLE 26 EXPORT DATA FOR HS CODE 283650 (CALCIUM CARBONATE), 2021–2025 (TONS) 112.
TABLE 27 IMPORT DATA FOR HS CODE 250100 (SALTS,.
INCL. TABLE SALT AND DENATURED SALT, AND PURE SODIUM CHLORIDE), 2021–2025 (USD) 112.
TABLE 28 IMPORT DATA FOR HS CODE 250100 (SALTS,.
INCL. TABLE SALT AND DENATURED SALT, AND PURE SODIUM CHLORIDE), 2021–2025 (TONS) 113.
TABLE 29 EXPORT DATA FOR HS CODE 250100 (SALTS,.
INCL. TABLE SALT AND DENATURED SALT, AND PURE SODIUM CHLORIDE), 2021–2025 (USD) 113.
TABLE 30 EXPORT DATA FOR HS CODE 250100 (SALTS,.
INCL. TABLE SALT AND DENATURED SALT, AND PURE SODIUM CHLORIDE), 2021–2025 (TONS) 114.
TABLE 31 IMPORT DATA FOR HS CODE 290543 (MANNITOL), 2021–2025 (USD) 114.
TABLE 32 IMPORT DATA FOR HS CODE 290543 (MANNITOL), 2021–2025 (USD) 115.
TABLE 33 EXPORT DATA FOR HS CODE 290543 (MANNITOL), 2021–2025 (USD) 115.
TABLE 34 EXPORT DATA FOR HS CODE 290543 (MANNITOL), 2021–2025 (TONS) 116.
TABLE 35 IMPORT DATA FOR HS CODE: 3912 (CELLULOSE AND ITS CHEMICAL DERIVATIVES,.
N.E.S., IN PRIMARY FORMS), 2021–2025 (USD) 116.
TABLE 36 IMPORT DATA FOR HS CODE: 3912 (CELLULOSE AND ITS CHEMICAL DERIVATIVES,.
N.E.S., IN PRIMARY FORMS), 2021–2025 (TONS) 117.
TABLE 37 EXPORT DATA FOR HS CODE: 3912 (CELLULOSE AND ITS CHEMICAL DERIVATIVES,.
N.E.S., IN PRIMARY FORMS), 2021–2025 (USD) 117.
TABLE 38 EXPORT DATA FOR HS CODE: 3912 (CELLULOSE AND ITS CHEMICAL DERIVATIVES,.
N.E.S., IN PRIMARY FORMS), 2021–2025 (TONS) 118.
TABLE 39 PHARMACEUTICAL EXCIPIENTS MARKET: KEY CONFERENCES & EVENTS,.
2026–2027 118.
TABLE 40 US ADJUSTED RECIPROCAL TARIFF RATES 123.
TABLE 41 IMPACT ANALYSIS ON END-USE INDUSTRIES 126.
TABLE 42 PHARMACEUTICAL EXCIPIENTS MARKET: TECHNOLOGY/PRODUCT ROADMAP 128.
TABLE 43 DETAILED ANALYSIS OF KEY PATENTS IN PHARMACEUTICAL EXCIPIENTS MARKET 130.
TABLE 44 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 136.
TABLE 45 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 137.
TABLE 46 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 137.
TABLE 47 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 138.
TABLE 48 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 138.
TABLE 49 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT (%) 144.
TABLE 50 KEY BUYING CRITERIA, BY END USER 145.
TABLE 51 PHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 149.
TABLE 52 PHARMACEUTICAL EXCIPIENTS MARKET FOR ORGANIC CHEMICALS, BY TYPE,.
2023–2031 (USD MILLION) 150.
TABLE 53 PHARMACEUTICAL EXCIPIENTS MARKET FOR ORGANIC CHEMICALS, BY REGION,.
2023–2031 (USD MILLION) 150.
TABLE 54 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR ORGANIC CHEMICALS, BY COUNTRY, 2023–2031 (USD MILLION) 150.
TABLE 55 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR ORGANIC CHEMICALS,.
BY COUNTRY, 2023–2031 (USD MILLION) 151.
TABLE 56 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR ORGANIC CHEMICALS, BY COUNTRY, 2023–2031 (USD MILLION) 151.
TABLE 57 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR ORGANIC CHEMICALS, BY COUNTRY, 2023–2031 (USD MILLION) 151.
TABLE 58 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR ORGANIC CHEMICALS, BY COUNTRY, 2023–2031 (USD MILLION) 152.
TABLE 59 PHARMACEUTICAL EXCIPIENTS MARKET FOR OLEOCHEMICALS, BY TYPE,.
2023–2031 (USD MILLION) 152.
TABLE 60 PHARMACEUTICAL EXCIPIENTS MARKET FOR OLEOCHEMICALS, BY REGION,.
2023–2031 (USD MILLION) 153.
TABLE 61 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR OLEOCHEMICALS, BY COUNTRY, 2023–2031 (USD MILLION) 153.
TABLE 62 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR OLEOCHEMICALS,.
BY COUNTRY, 2023–2031 (USD MILLION) 153.
TABLE 63 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR OLEOCHEMICALS,.
BY COUNTRY, 2023–2031 (USD MILLION) 154.
TABLE 64 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR OLEOCHEMICALS, BY COUNTRY, 2023–2031 (USD MILLION) 154.
TABLE 65 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR OLEOCHEMICALS,.
BY COUNTRY, 2023–2031 (USD MILLION) 154.
TABLE 66 PHARMACEUTICAL EXCIPIENTS MARKET FOR FATTY ALCOHOLS, BY REGION,.
2023–2031 (USD MILLION) 155.
TABLE 67 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR FATTY ALCOHOLS, BY COUNTRY, 2023–2031 (USD MILLION) 156.
TABLE 68 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR FATTY ALCOHOLS,.
BY COUNTRY, 2023–2031 (USD MILLION) 156.
TABLE 69 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR FATTY ALCOHOLS,.
BY COUNTRY, 2023–2031 (USD MILLION) 156.
TABLE 70 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR FATTY ALCOHOLS, BY COUNTRY, 2023–2031 (USD MILLION) 157.
TABLE 71 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR FATTY ALCOHOLS,.
BY COUNTRY, 2023–2031 (USD MILLION) 157.
TABLE 72 PHARMACEUTICAL EXCIPIENTS MARKET FOR MINERAL STEARATES, BY REGION,.
2023–2031 (USD MILLION) 158.
TABLE 73 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR MINERAL STEARATES, BY COUNTRY, 2023–2031 (USD MILLION) 158.
TABLE 74 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR MINERAL STEARATES,.
BY COUNTRY, 2023–2031 (USD MILLION) 158.
TABLE 75 ASIA PACIFIC PHARMACEUTICAL EXCIPIENTS MARKET FOR MINERAL STEARATES, BY COUNTRY, 2023–2031 (USD MILLION) 159.
TABLE 76 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR MINERAL STEARATES, BY COUNTRY, 2023–2031 (USD MILLION) 159.
TABLE 77 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR MINERAL STEARATES, BY COUNTRY, 2023–2031 (USD MILLION) 159.
TABLE 78 PHARMACEUTICAL EXCIPIENTS MARKET FOR GLYCERIN, BY REGION,.
2023–2031 (USD MILLION) 160.
TABLE 79 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR GLYCERIN,.
BY COUNTRY, 2023–2031 (USD MILLION) 160.
TABLE 80 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR GLYCERIN, BY COUNTRY,.
2023–2031 (USD MILLION) 161.
TABLE 81 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR GLYCERIN,.
BY COUNTRY, 2023–2031 (USD MILLION) 161.
TABLE 82 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR GLYCERIN,.
BY COUNTRY, 2023–2031 (USD MILLION) 161.
TABLE 83 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR GLYCERIN,.
BY COUNTRY, 2023–2031 (USD MILLION) 162.
TABLE 84 PHARMACEUTICAL EXCIPIENTS MARKET FOR OTHER OLEOCHEMICALS, BY REGION,.
2023–2031 (USD MILLION) 162.
TABLE 85 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR OTHER OLEOCHEMICALS, BY COUNTRY, 2023–2031 (USD MILLION) 163.
TABLE 86 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR OTHER OLEOCHEMICALS, BY COUNTRY, 2023–2031 (USD MILLION) 163.
TABLE 87 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR OTHER OLEOCHEMICALS, BY COUNTRY, 2023–2031 (USD MILLION) 163.
TABLE 88 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR OTHER OLEOCHEMICALS, BY COUNTRY, 2023–2031 (USD MILLION) 164.
TABLE 89 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR OTHER OLEOCHEMICALS, BY COUNTRY, 2023–2031 (USD MILLION) 164.
TABLE 90 PHARMACEUTICAL EXCIPIENTS MARKET FOR CARBOHYDRATES, BY TYPE,.
2023–2031 (USD MILLION) 165.
TABLE 91 PHARMACEUTICAL EXCIPIENTS MARKET FOR CARBOHYDRATES, BY REGION,.
2023–2031 (USD MILLION) 165.
TABLE 92 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR CARBOHYDRATES, BY COUNTRY, 2023–2031 (USD MILLION) 165.
TABLE 93 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR CARBOHYDRATES,.
BY COUNTRY, 2023–2031 (USD MILLION) 166.
TABLE 94 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR CARBOHYDRATES,.
BY COUNTRY, 2023–2031 (USD MILLION) 166.
TABLE 95 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR CARBOHYDRATES, BY COUNTRY, 2023–2031 (USD MILLION) 166.
TABLE 96 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR CARBOHYDRATES,.
BY COUNTRY, 2023–2031 (USD MILLION) 167.
TABLE 97 PHARMACEUTICAL EXCIPIENTS MARKET FOR SUGARS, BY TYPE,.
2023–2031 (USD MILLION) 167.
TABLE 98 PHARMACEUTICAL EXCIPIENTS MARKET FOR SUGARS, BY REGION,.
2023–2031 (USD MILLION) 168.
TABLE 99 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR SUGARS,.
BY COUNTRY, 2023–2031 (USD MILLION) 168.
TABLE 100 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR SUGARS, BY COUNTRY,.
2023–2031 (USD MILLION) 168.
TABLE 101 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR SUGARS, BY COUNTRY,.
2023–2031 (USD MILLION) 169.
TABLE 102 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR SUGARS,.
BY COUNTRY, 2023–2031 (USD MILLION) 169.
TABLE 103 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR SUGARS,.
BY COUNTRY, 2023–2031 (USD MILLION) 169.
TABLE 104 PHARMACEUTICAL EXCIPIENTS MARKET FOR ACTUAL SUGARS, BY TYPE,.
2023–2031 (USD MILLION) 170.
TABLE 105 PHARMACEUTICAL EXCIPIENTS MARKET FOR ACTUAL SUGARS, BY REGION,.
2023–2031 (USD MILLION) 171.
TABLE 106 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR ACTUAL SUGARS, BY COUNTRY, 2023–2031 (USD MILLION) 171.
TABLE 107 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR ACTUAL SUGARS,.
BY COUNTRY, 2023–2031 (USD MILLION) 171.
TABLE 108 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR ACTUAL SUGARS,.
BY COUNTRY, 2023–2031 (USD MILLION) 172.
TABLE 109 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR ACTUAL SUGARS,.
BY COUNTRY, 2023–2031 (USD MILLION) 172.
TABLE 110 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR ACTUAL SUGARS,.
BY COUNTRY, 2023–2031 (USD MILLION) 172.
TABLE 111 PHARMACEUTICAL EXCIPIENTS MARKET FOR LACTOSE, BY REGION,.
2023–2031 (USD MILLION) 173.
TABLE 112 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR LACTOSE,.
BY COUNTRY, 2023–2031 (USD MILLION) 173.
TABLE 113 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR LACTOSE, BY COUNTRY,.
2023–2031 (USD MILLION) 174.
TABLE 114 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR LACTOSE, BY COUNTRY,.
2023–2031 (USD MILLION) 174.
TABLE 115 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR LACTOSE,.
BY COUNTRY, 2023–2031 (USD MILLION) 174.
TABLE 116 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR LACTOSE,.
BY COUNTRY, 2023–2031 (USD MILLION) 175.
TABLE 117 PHARMACEUTICAL EXCIPIENTS MARKET FOR SUCROSE, BY REGION,.
2023–2031 (USD MILLION) 175.
TABLE 118 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR SUCROSE,.
BY COUNTRY, 2023–2031 (USD MILLION) 176.
TABLE 119 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR SUCROSE, BY COUNTRY,.
2023–2031 (USD MILLION) 176.
TABLE 120 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR SUCROSE,.
BY COUNTRY, 2023–2031 (USD MILLION) 176.
TABLE 121 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR SUCROSE,.
BY COUNTRY, 2023–2031 (USD MILLION) 177.
TABLE 122 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR SUCROSE,.
BY COUNTRY, 2023–2031 (USD MILLION) 177.
TABLE 123 PHARMACEUTICAL EXCIPIENTS MARKET FOR DEXTROSE (D-GLUCOSE), BY REGION,.
2023–2031 (USD MILLION) 178.
TABLE 124 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR DEXTROSE (D-GLUCOSE), BY COUNTRY, 2023–2031 (USD MILLION) 178.
TABLE 125 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR DEXTROSE (D-GLUCOSE), BY COUNTRY, 2023–2031 (USD MILLION) 178.
TABLE 126 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR DEXTROSE (D-GLUCOSE), BY COUNTRY, 2023–2031 (USD MILLION) 179.
TABLE 127 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR DEXTROSE (D-GLUCOSE), BY COUNTRY, 2023–2031 (USD MILLION) 179.
TABLE 128 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR DEXTROSE (D-GLUCOSE), BY COUNTRY, 2023–2031 (USD MILLION) 179.
TABLE 129 PHARMACEUTICAL EXCIPIENTS MARKET FOR SUGAR ALCOHOLS, BY TYPE,.
2023–2031 (USD MILLION) 180.
TABLE 130 PHARMACEUTICAL EXCIPIENTS MARKET FOR SUGAR ALCOHOLS, BY REGION,.
2023–2031 (USD MILLION) 181.
TABLE 131 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR SUGAR ALCOHOLS, BY COUNTRY, 2023–2031 (USD MILLION) 181.
TABLE 132 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR SUGAR ALCOHOLS,.
BY COUNTRY, 2023–2031 (USD MILLION) 181.
TABLE 133 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR SUGAR ALCOHOLS,.
BY COUNTRY, 2023–2031 (USD MILLION) 182.
TABLE 134 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR SUGAR ALCOHOLS, BY COUNTRY, 2023–2031 (USD MILLION) 182.
TABLE 135 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR SUGAR ALCOHOLS,.
BY COUNTRY, 2023–2031 (USD MILLION) 182.
TABLE 136 PHARMACEUTICAL EXCIPIENTS MARKET FOR SORBITOL, BY REGION,.
2023–2031 (USD MILLION) 183.
TABLE 137 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR SORBITOL,.
BY COUNTRY, 2023–2031 (USD MILLION) 183.
TABLE 138 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR SORBITOL, BY COUNTRY,.
2023–2031 (USD MILLION) 184.
TABLE 139 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR SORBITOL,.
BY COUNTRY, 2023–2031 (USD MILLION) 184.
TABLE 140 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR SORBITOL,.
BY COUNTRY, 2023–2031 (USD MILLION) 184.
TABLE 141 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR SORBITOL,.
BY COUNTRY, 2023–2031 (USD MILLION) 185.
TABLE 142 PHARMACEUTICAL EXCIPIENTS MARKET FOR MANNITOL, BY REGION,.
2023–2031 (USD MILLION) 185.
TABLE 143 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR MANNITOL,.
BY COUNTRY, 2023–2031 (USD MILLION) 186.
TABLE 144 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR MANNITOL, BY COUNTRY,.
2023–2031 (USD MILLION) 186.
TABLE 145 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR MANNITOL,.
BY COUNTRY, 2023–2031 (USD MILLION) 186.
TABLE 146 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR MANNITOL,.
BY COUNTRY, 2023–2031 (USD MILLION) 187.
TABLE 147 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR MANNITOL,.
BY COUNTRY, 2023–2031 (USD MILLION) 187.
TABLE 148 PHARMACEUTICAL EXCIPIENTS MARKET FOR OTHER SUGAR ALCOHOLS,.
BY REGION, 2023–2031 (USD MILLION) 188.
TABLE 149 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR OTHER SUGAR ALCOHOLS, BY COUNTRY, 2023–2031 (USD MILLION) 188.
TABLE 150 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR OTHER SUGAR ALCOHOLS, BY COUNTRY, 2023–2031 (USD MILLION) 188.
TABLE 151 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR OTHER SUGAR ALCOHOLS, BY COUNTRY, 2023–2031 (USD MILLION) 189.
TABLE 152 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR OTHER SUGAR ALCOHOLS, BY COUNTRY, 2023–2031 (USD MILLION) 189.
TABLE 153 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR OTHER SUGAR ALCOHOLS, BY COUNTRY, 2023–2031 (USD MILLION) 189.
TABLE 154 PHARMACEUTICAL EXCIPIENTS MARKET FOR ARTIFICIAL SWEETENERS,.
BY REGION, 2023–2031 (USD MILLION) 191.
TABLE 155 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR ARTIFICIAL SWEETENERS, BY COUNTRY, 2023–2031 (USD MILLION) 191.
TABLE 156 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR ARTIFICIAL SWEETENERS, BY COUNTRY, 2023–2031 (USD MILLION) 191.
TABLE 157 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR ARTIFICIAL SWEETENERS, BY COUNTRY, 2023–2031 (USD MILLION) 192.
TABLE 158 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR ARTIFICIAL SWEETENERS, BY COUNTRY, 2023–2031 (USD MILLION) 192.
TABLE 159 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR ARTIFICIAL SWEETENERS, BY COUNTRY, 2023–2031 (USD MILLION) 192.
TABLE 160 PHARMACEUTICAL EXCIPIENTS MARKET FOR CELLULOSE, BY TYPE,.
2023–2031 (USD MILLION) 193.
TABLE 161 PHARMACEUTICAL EXCIPIENTS MARKET FOR CELLULOSE, BY REGION,.
2023–2031 (USD MILLION) 194.
TABLE 162 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR CELLULOSE,.
BY COUNTRY, 2023–2031 (USD MILLION) 194.
TABLE 163 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR CELLULOSE, BY COUNTRY,.
2023–2031 (USD MILLION) 194.
TABLE 164 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR CELLULOSE,.
BY COUNTRY, 2023–2031 (USD MILLION) 195.
TABLE 165 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR CELLULOSE,.
BY COUNTRY, 2023–2031 (USD MILLION) 195.
TABLE 166 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR CELLULOSE,.
BY COUNTRY, 2023–2031 (USD MILLION) 195.
TABLE 167 PHARMACEUTICAL EXCIPIENTS MARKET FOR MICROCRYSTALLINE CELLULOSE,.
BY REGION, 2023–2031 (USD MILLION) 196.
TABLE 168 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR MICROCRYSTALLINE CELLULOSE, BY COUNTRY, 2023–2031 (USD MILLION) 197.
TABLE 169 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR MICROCRYSTALLINE CELLULOSE, BY COUNTRY, 2023–2031 (USD MILLION) 197.
TABLE 170 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR MICROCRYSTALLINE CELLULOSE, BY COUNTRY, 2023–2031 (USD MILLION) 197.
TABLE 171 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR MICROCRYSTALLINE CELLULOSE, BY COUNTRY, 2023–2031 (USD MILLION) 198.
TABLE 172 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR MICROCRYSTALLINE CELLULOSE, BY COUNTRY, 2023–2031 (USD MILLION) 198.
TABLE 173 PHARMACEUTICAL EXCIPIENTS MARKET FOR CELLULOSE ETHERS, BY REGION,.
2023–2031 (USD MILLION) 199.
TABLE 174 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR CELLULOSE ETHERS, BY COUNTRY, 2023–2031 (USD MILLION) 199.
TABLE 175 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR CELLULOSE ETHERS,.
BY COUNTRY, 2023–2031 (USD MILLION) 200.
TABLE 176 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR CELLULOSE ETHERS, BY COUNTRY, 2023–2031 (USD MILLION) 200.
TABLE 177 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR CELLULOSE ETHERS, BY COUNTRY, 2023–2031 (USD MILLION) 200.
TABLE 178 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR CELLULOSE ETHERS, BY COUNTRY, 2023–2031 (USD MILLION) 201.
TABLE 179 PHARMACEUTICAL EXCIPIENTS MARKET FOR CMC & CROSCARMELLOSE SODIUM, BY REGION, 2023–2031 (USD MILLION) 202.
TABLE 180 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR CMC & CROSCARMELLOSE SODIUM, BY COUNTRY, 2023–2031 (USD MILLION) 202.
TABLE 181 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR CMC & CROSCARMELLOSE SODIUM, BY COUNTRY, 2023–2031 (USD MILLION) 202.
TABLE 182 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR CMC & CROSCARMELLOSE SODIUM, BY COUNTRY, 2023–2031 (USD MILLION) 203.
TABLE 183 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR CMC & CROSCARMELLOSE SODIUM, BY COUNTRY, 2023–2031 (USD MILLION) 203.
TABLE 184 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR CMC & CROSCARMELLOSE SODIUM, BY COUNTRY, 2023–2031 (USD MILLION) 203.
TABLE 185 PHARMACEUTICAL EXCIPIENTS MARKET FOR CELLULOSE ESTERS, BY REGION,.
2023–2031 (USD MILLION) 204.
TABLE 186 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR CELLULOSE ESTERS, BY COUNTRY, 2023–2031 (USD MILLION) 204.
TABLE 187 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR CELLULOSE ESTERS,.
BY COUNTRY, 2023–2031 (USD MILLION) 205.
TABLE 188 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR CELLULOSE ESTERS, BY COUNTRY, 2023–2031 (USD MILLION) 205.
TABLE 189 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR CELLULOSE ESTERS, BY COUNTRY, 2023–2031 (USD MILLION) 205.
TABLE 190 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR CELLULOSE ESTERS, BY COUNTRY, 2023–2031 (USD MILLION) 206.
TABLE 191 PHARMACEUTICAL EXCIPIENTS MARKET FOR STARCH, BY TYPE,.
2023–2031 (USD MILLION) 206.
TABLE 192 PHARMACEUTICAL EXCIPIENTS MARKET FOR STARCH, BY REGION,.
2023–2031 (USD MILLION) 207.
TABLE 193 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR STARCH,.
BY COUNTRY, 2023–2031 (USD MILLION) 207.
TABLE 194 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR STARCH, BY COUNTRY,.
2023–2031 (USD MILLION) 207.
TABLE 195 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR STARCH, BY COUNTRY,.
2023–2031 (USD MILLION) 208.
TABLE 196 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR STARCH,.
BY COUNTRY, 2023–2031 (USD MILLION) 208.
TABLE 197 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR STARCH, BY COUNTRY,.
2023–2031 (USD MILLION) 208.
TABLE 198 PHARMACEUTICAL EXCIPIENTS MARKET FOR MODIFIED STARCH, BY REGION,.
2023–2031 (USD MILLION) 209.
TABLE 199 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR MODIFIED STARCH, BY COUNTRY, 2023–2031 (USD MILLION) 210.
TABLE 200 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR MODIFIED STARCH,.
BY COUNTRY, 2023–2031 (USD MILLION) 210.
TABLE 201 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR MODIFIED STARCH,.
BY COUNTRY, 2023–2031 (USD MILLION) 210.
TABLE 202 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR MODIFIED STARCH, BY COUNTRY, 2023–2031 (USD MILLION) 211.
TABLE 203 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR MODIFIED STARCH,.
BY COUNTRY, 2023–2031 (USD MILLION) 211.
TABLE 204 PHARMACEUTICAL EXCIPIENTS MARKET FOR DRIED STARCH, BY REGION,.
2023–2031 (USD MILLION) 212.
TABLE 205 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR DRIED STARCH,.
BY COUNTRY, 2023–2031 (USD MILLION) 212.
TABLE 206 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR DRIED STARCH,.
BY COUNTRY, 2023–2031 (USD MILLION) 212.
TABLE 207 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR DRIED STARCH,.
BY COUNTRY, 2023–2031 (USD MILLION) 213.
TABLE 208 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR DRIED STARCH,.
BY COUNTRY, 2023–2031 (USD MILLION) 213.
TABLE 209 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR DRIED STARCH,.
BY COUNTRY, 2023–2031 (USD MILLION) 213.
TABLE 210 PHARMACEUTICAL EXCIPIENTS MARKET FOR CONVERTED STARCH, BY REGION,.
2023–2031 (USD MILLION) 214.
TABLE 211 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR CONVERTED STARCH, BY COUNTRY, 2023–2031 (USD MILLION) 214.
TABLE 212 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR CONVERTED STARCH,.
BY COUNTRY, 2023–2031 (USD MILLION) 215.
TABLE 213 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR CONVERTED STARCH, BY COUNTRY, 2023–2031 (USD MILLION) 215.
TABLE 214 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR CONVERTED STARCH, BY COUNTRY, 2023–2031 (USD MILLION) 215.
TABLE 215 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR CONVERTED STARCH, BY COUNTRY, 2023–2031 (USD MILLION) 216.
TABLE 216 PHARMACEUTICAL EXCIPIENTS MARKET FOR PETROCHEMICALS, BY TYPE,.
2023–2031 (USD MILLION) 216.
TABLE 217 PHARMACEUTICAL EXCIPIENTS MARKET FOR PETROCHEMICALS, BY REGION,.
2023–2031 (USD MILLION) 217.
TABLE 218 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR PETROCHEMICALS, BY COUNTRY, 2023–2031 (USD MILLION) 217.
TABLE 219 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR PETROCHEMICALS,.
BY COUNTRY, 2023–2031 (USD MILLION) 218.
TABLE 220 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR PETROCHEMICALS,.
BY COUNTRY, 2023–2031 (USD MILLION) 218.
TABLE 221 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR PETROCHEMICALS, BY COUNTRY, 2023–2031 (USD MILLION) 218.
TABLE 222 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR PETROCHEMICALS,.
BY COUNTRY, 2023–2031 (USD MILLION) 219.
TABLE 223 PHARMACEUTICAL EXCIPIENTS MARKET FOR GLYCOLS, BY TYPE,.
2023–2031 (USD MILLION) 220.
TABLE 224 PHARMACEUTICAL EXCIPIENTS MARKET FOR GLYCOLS, BY REGION,.
2023–2031 (USD MILLION) 220.
TABLE 225 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR GLYCOLS,.
BY COUNTRY, 2023–2031 (USD MILLION) 220.
TABLE 226 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR GLYCOLS, BY COUNTRY,.
2023–2031 (USD MILLION) 221.
TABLE 227 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR GLYCOLS,.
BY COUNTRY, 2023–2031 (USD MILLION) 221.
TABLE 228 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR GLYCOLS,.
BY COUNTRY, 2023–2031 (USD MILLION) 221.
TABLE 229 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR GLYCOLS,.
BY COUNTRY, 2023–2031 (USD MILLION) 222.
TABLE 230 PHARMACEUTICAL EXCIPIENTS MARKET FOR POLYETHYLENE GLYCOL (PEG),.
BY REGION, 2023–2031 (USD MILLION) 222.
TABLE 231 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR POLYETHYLENE GLYCOL (PEG), BY COUNTRY, 2023–2031 (USD MILLION) 223.
TABLE 232 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR POLYETHYLENE GLYCOL (PEG), BY COUNTRY, 2023–2031 (USD MILLION) 223.
TABLE 233 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR POLYETHYLENE GLYCOL (PEG), BY COUNTRY, 2023–2031 (USD MILLION) 223.
TABLE 234 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR POLYETHYLENE GLYCOL (PEG), BY COUNTRY, 2023–2031 (USD MILLION) 224.
TABLE 235 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR POLYETHYLENE GLYCOL (PEG), BY COUNTRY, 2023–2031 (USD MILLION) 224.
TABLE 236 PHARMACEUTICAL EXCIPIENTS MARKET FOR PROPYLENE GLYCOL (PG),.
BY REGION, 2023–2031 (USD MILLION) 225.
TABLE 237 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR PROPYLENE GLYCOL (PG), BY COUNTRY, 2023–2031 (USD MILLION) 225.
TABLE 238 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR PROPYLENE GLYCOL (PG), BY COUNTRY, 2023–2031 (USD MILLION) 225.
TABLE 239 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR PROPYLENE GLYCOL (PG), BY COUNTRY, 2023–2031 (USD MILLION) 226.
TABLE 240 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR PROPYLENE GLYCOL (PG), BY COUNTRY, 2023–2031 (USD MILLION) 226.
TABLE 241 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR PROPYLENE GLYCOL (PG), BY COUNTRY, 2023–2031 (USD MILLION) 226.
TABLE 242 PHARMACEUTICAL EXCIPIENTS MARKET FOR POVIDONES, BY REGION,.
2023–2031 (USD MILLION) 227.
TABLE 243 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR POVIDONES,.
BY COUNTRY, 2023–2031 (USD MILLION) 227.
TABLE 244 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR POVIDONES, BY COUNTRY,.
2023–2031 (USD MILLION) 228.
TABLE 245 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR POVIDONES,.
BY COUNTRY, 2023–2031 (USD MILLION) 228.
TABLE 246 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR POVIDONES,.
BY COUNTRY, 2023–2031 (USD MILLION) 228.
TABLE 247 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR POVIDONES,.
BY COUNTRY, 2023–2031 (USD MILLION) 229.
TABLE 248 PHARMACEUTICAL EXCIPIENTS MARKET FOR MINERAL HYDROCARBONS, BY TYPE,.
2023–2031 (USD MILLION) 230.
TABLE 249 PHARMACEUTICAL EXCIPIENTS MARKET FOR MINERAL HYDROCARBONS,.
BY REGION, 2023–2031 (USD MILLION) 230.
TABLE 250 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR MINERAL HYDROCARBONS, BY COUNTRY, 2023–2031 (USD MILLION) 230.
TABLE 251 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR MINERAL HYDROCARBONS, BY COUNTRY, 2023–2031 (USD MILLION) 231.
TABLE 252 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR MINERAL HYDROCARBONS, BY COUNTRY, 2023–2031 (USD MILLION) 231.
TABLE 253 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR MINERAL HYDROCARBONS, BY COUNTRY, 2023–2031 (USD MILLION) 231.
TABLE 254 MIDDLE EAST: PHARMACEUTICAL EXCIPIENTS MARKET FOR MINERAL HYDROCARBONS, BY COUNTRY, 2023–2031 (USD MILLION) 232.
TABLE 255 PHARMACEUTICAL EXCIPIENTS MARKET FOR PETROLATUM, BY REGION,.
2023–2031 (USD MILLION) 232.
TABLE 256 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET FOR PETROLATUM,.
BY COUNTRY, 2023–2031 (USD MILLION) 233.
TABLE 257 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET FOR PETROLATUM,.
BY COUNTRY, 2023–2031 (USD MILLION) 233.
TABLE 258 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET FOR PETROLATUM,.
BY COUNTRY, 2023–2031 (USD MILLION) 233.